Silexion Therapeutics’ SIL204 emerges as a potential game-changer in KRAS-driven cancer treatment

Silexion Therapeutics (NASDAQ: SLXN) has taken a major step forward in oncology research, unveiling new preclinical data on its experimental therapy, SIL204. The clinical-stage biotechnology ... Read More